DISCLAIMER: GoldInvestors.news is not a registered investment, legal or tax advisor or broker/dealer. All investment/financial opinions expressed by GoldInvestors.news are from the personal research and experience of the owner of the site and are intended as educational material. Although best efforts are made to ensure that all information is accurate and up to date, occasionally unintended errors and misprints may occur.

America’s weight loss drug boom is turning into a retail land grab, and the biggest chains in the country are lining up for a much richer prize than a single prescription.

As employers pull back coverage for drugs such as Wegovy and Zepbound, more consumers are being pushed into direct to consumer prescription channels, opening the door for Walmart, Costco, CVS and Amazon to capture a larger share of a fast growing health care market.

For these companies, the real money is not just in filling a GLP 1 prescription. It is in winning a recurring customer who may also buy groceries, household goods, clothing and other medications while staying tied to the same retail ecosystem for months or years.

“Retailers are betting that if they can become the front door for obesity care, they’ll earn a relationship that extends far beyond a single GLP-1 prescription,” said Eric Bormel, managing director specializing in digital healthcare at Solomon Partners’ healthcare group.

Here's What They're Not Telling You About Your Retirement

That shift helps explain why major chains are willing to compete aggressively even as prices face pressure. The prescription becomes a customer acquisition tool, while the refill schedule creates a dependable stream of visits that most retailers would pay heavily to generate.

“Everyone recognizes that obesity treatment is becoming a longitudinal consumer relationship,” Bormel said. That is a sharp contrast to early fears that weight loss drugs would hurt retailers by reducing impulse purchases and grocery demand.

Jackie Swanson, managing partner at Gartner Consulting, said the refill cycle is unusually powerful in a retail business that constantly fights for repeat traffic. “In a retail industry that spends billions chasing foot traffic, that is the most reliable recurring customer relationship on the market,” she said.

Walmart’s role as a pickup point for LillyDirect gives it a simple advantage because customers must enter the store to collect the medicine. “Pharmacy lock-in is loyalty-program economics applied to medicine, and it works because the refill, unlike almost everything else in retail, is non-negotiable,” Swanson said.

This Could Be the Most Important Video Gun Owners Watch All Year

The pricing models also look a lot like retail loyalty systems. Swanson said LillyDirect’s $299 to $449 monthly cash prices, with better pricing tied to refilling within 45 days, are “a loyalty program dressed as a discount schedule,” while NovoCare’s $199 introductory price that later rises to $349 is a “classic acquisition funnel.”

Costco is playing the same game through its Sesame partnership, with Wegovy priced around $349 and tied to membership. “So the prescription now helps sell the $65 card,” Swanson said.

Walmart has nearly 4,600 pharmacies and ranks as the nation’s fifth largest prescription provider, but it still trails CVS and Walgreens in market share. Its Better Care Services platform now packages GLP 1 prescriptions with weight management support, nutrition coaching, fitness tools and artificial intelligence driven coaching as it tries to turn pharmacy traffic into broader retail loyalty.

Amazon is also moving fast after years of uneven health care experiments. Through Amazon One Medical and Amazon Pharmacy, it is offering insured patients GLP 1 access for as little as $25 a month, with same day delivery already available in nearly 3,000 cities and more markets expected by year end.

The opportunity is large, but the profit math is not automatic. “Sales dollars are a lot bigger than the margin dollars,” Kroger CEO Rodney McMullen said in 2023, adding, “The impact on profitability is pretty narrow.”

Retailers also have a mixed record in health care. Walmart closed its health clinics and virtual care service in 2024, Amazon shut down Amazon Care and walked away from Haven, and CVS has scaled back parts of its MinuteClinic footprint after discovering that health care is not always as simple as selling paper towels.

Still, employer retrenchment is handing retailers a fresh opening. Mercer found that 6% of large employers dropped GLP 1 coverage this year, while the drugs’ share of claims jumped to 11.4% from 6.9% in 2023, and Cigna recently said it would stop covering the medicines for its own employees.

“Every patient who loses coverage is choosing a new front door for care this year, and retailers are competing to be that door at the exact moment of the decision. Real affordability gets delivered; a customer relationship gets acquired; both statements are true simultaneously,” Swanson said.

Independent pharmacies may be the obvious casualties. “Smaller pharmacies stand to lose volume for sure,” said Seth Friedman, pharmacy & health plan services practice leader at Gallagher.

Dared Price, who owns nine pharmacies in small Kansas towns, said the shift is already hitting home. “It is frustrating to me to not be able to provide the same access to our patients that they do to CVS or Costco,” Price said.

Price also warned that fragmented care can create medical risks when local pharmacists cannot see a patient’s full drug profile. “My system won’t flag any drug interactions with GLP drugs and there are drug interactions that can be dangerous,” he said.

CVS argues that its pharmacists are equipped to support patients beyond the transaction. “Access is only part of the equation with GLP-1 medications. Patients also need support to stay on therapy and see results,” said Sid Tenneti, senior vice president and interim president, pharmacy and consumer wellness.

Some obesity care specialists remain wary of a race built mostly around price and scale. “My view on this is that the drugs are not the solution by themselves; they are a powerful tool. But the medication alone doesn’t work that well. People do much better when cared for by expert clinicians,” said Elina Onitskansky, founder & CEO of Ilant Health, adding, “I don’t think fragmentation helps.”

For now, the market is moving toward the companies with the biggest networks, the deepest technology budgets and the most convenient pickup points. Price said smaller operators have been left outside the deal flow, calling it “a travesty that there [aren’t]” better direct to consumer programs for independents.

DISCLAIMER: GoldInvestors.news is not a registered investment, legal or tax advisor or broker/dealer. All investment/financial opinions expressed by GoldInvestors.news are from the personal research and experience of the owner of the site and are intended as educational material. Although best efforts are made to ensure that all information is accurate and up to date, occasionally unintended errors and misprints may occur.